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Advanced tumors are often immunosuppressive. Intratu-
moral administration of adenovirus activates Toll-like
receptor signalling leading to production of pro-inflamma-
tory cytokines and activation of the innate immune sys-
tem. Oncolytic adenovirus causes immunogenic cancer
cell death and creates a danger signal at tumors, thus
undermining immunological tolerance towards tumors.
The release of tumor antigens from dying cancer cells
results in priming of a potent anti-tumor immune
response. This effect may be enhanced by the local pro-
duction of immunostimulatory molecules coded by the
virus. We present results of gene expression analysis of
tumors from a Phase I study with ONCOS-102, an oncoly-
tic adenovirus coding for GMCSF, in 12 patients with
refractory solid tumors.
A total of 9 intratumoral injections of ONCOS-102 were
given to each patient. Biopsies were collected at baseline
and 1 and 2 months after treatment initiation. RNA was
extracted from fresh-frozen biopsies using standard meth-
ods. Gene expression profiling was carried out using the
Illumina BeadChip platform. Data was normalized by
quantile method, probes presenting the same genes were
averaged, and the batch effects were adjusted using Com-
Bat pipeline, as implemented in Chipster (http://chipster.
csc.fi/). Finally, log2 fold-changes were computed by sub-
tracting baseline data from after treatment data. Network
and pathway analyses were conducted through the use of
IPA (Ingenuity ®Systems, www.ingenuity.com). A cutoff
value of 2-fold expression change was used to filter differ-
entially expressed genes and run core analysis to identify
underlying signaling networks and deregulated molecules.
A significant enrichment of genes involved in immune
cell trafficking, inflammatory response and antigen pre-
sentation were detected post treatment. A mesothelioma
patient showed a prominent post-treatment induction of
MAGE3-specific CD8+ T-cells in peripheral blood in
IFNg ELISPOT. Furthermore, a late decrease in meta-
bolic activity was observed in PET imaging 7.5 months
after treatment initiation during the follow-up period,
measured as a 47% decrease in total lesion glycolysis in
comparison to the imaging at 6 months. In the same
patient, upstream regulators driving differentially
expressed genes detected in the post treatment biopsy
included cytokines (INFG, TNF, IL1B, CCL2, CXCL10,
IL-17A, CD40LG), enzymes (FN1, NOS2, PTGS2,
PARP9), growth factors (BMP2, LEP), kinases (CHUK,
CRKL, IKBKB, IKBKG, ITK, STK11, SYK), transcrip-
tional regulators (IRF1, NFATC2, NFKBIA, STAT1,
STAT3, ZEB1, RELA), and transmembrane receptors
(B2M, CD40, IL6R, TLR2-4, TNFSF1B). Likely, these
events collectively induced a higher CD8+ mediated cyto-
toxic T cell response (GZMB, PRF1) post treatment.
Detailed analysis per patient will be presented at the
meeting.
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